May 6, 2020 / 12:13 AM / 2 months ago

Australia's CSL to start work on immunoglobulin product to treat COVID-19

May 6 (Reuters) - Australian biotech firm CSL Ltd said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.

The company’s unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.

CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.

Reporting by Nikhil Kurian Nainan in Bengaluru; Editing by Tom Hogue

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below